ClinicalTrials.gg
CompletedNCT00825630Updated Dec 20, 2022Results posted

13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)

A Phase 4 interventional study of Lansoprazole (Lanton) and Omeprezole (Losec) in Helicobacter Pylori Infection, sponsored by Meridian Bioscience, Inc.. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Meridian Bioscience, Inc. (part of SD Biosensor) · Phase 4, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Approximately 200 patients with suspected H.pylori will be tested with a 13C-Urea Breath Test (UBT) to ascertain H.pylori positive. 100 H.Pylori positive patients will tested before and after prescribed with one of the four selected Proton Pump Inhibitors (PPIs); 25 patients in each arm. This will provide information on the influence of PPIs on the UBT (Urea Breath Test). The aim of the trial is to observe the effect of different PPIs on the breath test and choose the optimal protocol of when to stop PPI. The hypothesis is that there will be a minimal effect on the UBT while using selected PPIs.

Read the detailed description

Adult subjects with suspected H pylori infection will be recruited and will undergo a 13C -Urea breath test (including citrica) with the BreathID test device. Those were found positive will undergo selected PPI treatment for 14 days and after 24 or 72 hours from the completion of the two weeks, will undergo a second breath test. Those found to be negative (false negative), will undergo additional breath tests.

  • Those subjects that underwent any antibiotic, bismuth or PPI therapy 4 weeks prior to the trial, are to be excluded.
  • Furthermore, pregnant or nursing women and subjects with an allergy or sensitivity to one of the tests substrates, will be excluded from the study.
02

Conditions studied

  • Helicobacter Pylori Infection

Keywords

  • HP
  • UBT
  • PPI
03

In context

Lead sponsor

Meridian Bioscience, Inc. is the lead sponsor of 27 studies on the registry; none are open to participants now.

First submitted before Meridian Bioscience, Inc. became part of SD Biosensor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with H.pylori infection.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy,
  • Nursing,
  • Antibiotic, bismuth or PPI treatment 2 weeks prior to trial,
  • Known sensitivity to Urea or citrica.
05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Active comparator
    Lansoprazole (Lanton)

    Patients with H.pylori infection will take one tablet a day of 20 mg Lansoprazole for 14 days orally in the morning

    Drug: Lansoprazole (Lanton)

  • Active comparator
    Omeprazole (Losec)

    Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning

    Drug: Omeprezole (Losec)

  • Active comparator
    Pantoprazole (Controloc)

    Patients with H.pylori infection will take one tablet a day of 40 mg of Pantoprazole for 14 days orally in the morning

    Drug: Pantoprazole(Controloc)

  • Active comparator
    Esomeprazole(Nexium)

    Patients with H.pylori infection will take one tablet a day of 20 mg Esomeprazole for 14 days orally on the morning

    Drug: Esomeprazole (Nexium)

Interventions

  • Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection

    Also known as: Lanton

  • Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection

    Also known as: Losec

  • Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection

    Also known as: Controloc

  • Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection

    Also known as: Nexium

06

What researchers measure

Primary outcomes

  1. Urea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped.

    Negative value is defined as delta over baseline (DOB) less than 5. The subjects who were positive (DOB\>=5) for H.Pylori and after PPI for 10 days repeated a breath with a negative (DOB\<5) were considered false negatives. The breath test has been cleared by the FDA in a 510(k) and has \> 96% accuracy.

    Time frame: 17 days

07

Results

Posted Oct 7, 2011
Limitations and caveats
It was hard to get people to agree to return for multiple tests within a few days, so the enrollment was difficult

Participant flow

Two out-patient clinics in hospitals will enroll subjects

Participant flow — Overall Study
MilestoneLansoprazole (Lanton)Omeprazole( Losec)Pantoprazole (Controloc)Esomeprazole (Nexium)
Started29621913
Completed29621913
Not completed0000

Outcome measures

PrimaryUrea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped.

Negative value is defined as delta over baseline (DOB) less than 5. The subjects who were positive (DOB\>=5) for H.Pylori and after PPI for 10 days repeated a breath with a negative (DOB\<5) were considered false negatives. The breath test has been cleared by the FDA in a 510(k) and has \> 96% accuracy.

Time frame:
17 days
Reported as:
Number · participants
Urea Breath Test Result (DOB > 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped.
participantsLansoprazole (Lanton)Omeprazole( Losec)Pantoprazole (Controloc)Esomeprazole (Nexium)
False negatives (DOB<5) after 3 days of no PPI1310
False negatives (DOB<5) after 1 day of no PPI2421

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lansoprazole (Lanton)—0/29 (0%)0/29 (0%)
Omeprazole( Losec)—0/62 (0%)0/62 (0%)
Pantoprazole (Controloc)—0/19 (0%)0/19 (0%)
Esomeprazole (Nexium)—0/13 (0%)0/13 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lansoprazole (Lanton)Omeprazole( Losec)Pantoprazole (Controloc)Esomeprazole (Nexium)Total
<=18 years00000
Between 18 and 65 years2655179107
>=65 years372416
Age, Continuous
Age, Continuous(years)Lansoprazole (Lanton)Omeprazole( Losec)Pantoprazole (Controloc)Esomeprazole (Nexium)Total
Mean52.86 ± 14.6752.48 ± 13.3551.84 ± 12.7855.38 ± 14.8452.46 ± 14.01
Sex: Female, Male
Sex: Female, Male(Participants)Lansoprazole (Lanton)Omeprazole( Losec)Pantoprazole (Controloc)Esomeprazole (Nexium)Total
Female204015782
Male9224641
Region of Enrollment
Region of Enrollment(participants)Lansoprazole (Lanton)Omeprazole( Losec)Pantoprazole (Controloc)Esomeprazole (Nexium)Total
Israel29621913123
H. Pyori Positive
H. Pyori Positive(particpants)Lansoprazole (Lanton)Omeprazole( Losec)Pantoprazole (Controloc)Esomeprazole (Nexium)Total
Number29621913123
08

Study locations

1 site
  • Rabin Medical Center
    Petah Tikva, 49100, Israel
09

References and documents

Publications

  • Shirin H, Frenkel D, Shevah O, Levine A, Bruck R, Moss SF, Niv Y, Avni Y. Effect of proton pump inhibitors on the continuous real time (13)C-urea breath test. Am J Gastroenterol. 2003 Jan;98(1):46-50. doi: 10.1111/j.1572-0241.2003.07187.x. PubMed 12526935 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2009
First posted
Jan 21, 2009
Start
Nov 2008
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Oct 7, 2011
Last update
Dec 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00825630
Responsible party
Sponsor
First posted
Jan 21, 2009
Start date
Nov 2008
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Oct 7, 2011
Last update
Dec 20, 2022

Study contacts

Haim Shirin, MD
principal investigator · Sharon Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lansoprazole · Omeprazole · Esomeprazole

Start the discussion